I prefer to look for GARP (growth at a reasonable price) stocks but also look for opportunities everywhere else. I don't have a specified time horizon. I invest in a stock for as long as my thesis holds true, and I get out when the facts change. In addition, I've developed market-beating algorithms with Python that have helped me find attractive investment opportunities within my own portfolio, and I have been investing since 2016.On top of that, I've worked at TipRanks as an analysis/news writer and even a ...

LOS ANGELES, Oct. 25, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ: MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Medpace reported its third quarter 2024 financial results on October 21, 2 ...

RADNOR, Pa., Oct. 24, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Medpace Holdings, Inc. (NASDAQ: MEDP) (“Medpace”). On October 21, 2024, during after-market hours, Medpace reported its third quarter 2024 financial results and cut its revenue guidance for full-year 2024. During an investor call held on October 22, 2024, Medpace indicated that the company had ...

RADNOR, Pa., Oct. 23, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Medpace Holdings, Inc. (NASDAQ: MEDP) ("Medpace").On October 21, 2024, during after-market hours, Medpace reported its third quarter 2024 financial results and cut its revenue guidance for full-year 2024. During an investor call held on October 22, 2024, Medpace indicated that the company had seen ...

Medpace Holdings, Inc. (NASDAQ:MEDP) Q3 2024 Earnings Conference Call October 22, 2024 9:00 AM ET Company Participants Lauren Morris - Director, Investor Relations August Troendle - Chief Executive Officer Jesse Geiger - President Kevin Brady - Chief Financial Officer Conference Call Participants David Windley - Jefferies Max Smock - William Blair Eric Coldwell - Baird Ann Hynes - Mizuho Dan Leonard - UBS Justin Bowers - DB Charles Rhyee - TD Cowen Jailendra Singh - Truist Securities Operator Good day, ladi ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock $0.01 par value MEDP NASDAQ Global Select Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________ FORM 10-Q ___________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or o TRANSITION REPORT PURSUANT ...

Medpace Holdings, Inc. MEDP shares are trading lower on Tuesday after reporting its third-quarter financial results yesterday.Revenue rose 8.3% year-over-year to $533.3 million, missing the consensus of $540.99 million.On a constant currency basis, revenue increased by 8.1% in the quarter. As of September 30, backlog rose by 8.8% to $2.927 billion.Net new business awards totaled $533.7 million for the third quarter of 2024, resulting in a net book-to-bill ratio of 1.00x, compared to $611.5 million in the pr ...

| --- | --- | |-------|-------| | | | | | | | | | FORWARD LOOKING STATEMENTS & NON-GAAP FINANCIAL MEASURES Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding our forecasted financial results and the effective ta ...

Medpace (MEDP) came out with quarterly earnings of $3.01 per share, beating the Zacks Consensus Estimate of $2.77 per share. This compares to earnings of $2.22 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 8.66%. A quarter ago, it was expected that this provider of outsourced clinical development services would post earnings of $2.52 per share when it actually produced earnings of $2.75, delivering a surprise of 9.13%. Over ...

Revenue Performance - Revenue for Q3 2024 was $533.3 million, an increase of 8.3% from $492.5 million in Q3 2023, with a backlog conversion rate of 18.2%[2] - Year-to-date revenue for 2024 was $1,572.5 million, reflecting a 13.3% increase from the prior year[7] - Full year 2024 revenue is forecasted to be between $2.090 billion and $2.130 billion, indicating growth of 10.8% to 12.9% over 2023[9] - Net revenue for the three months ended September 30, 2024, was $533,317,000, representing a 8.3% increase from $492,499,000 in the same period of 2023[19] Profitability Metrics - GAAP net income for Q3 2024 was $96.4 million, or $3.01 per diluted share, compared to $70.6 million, or $2.22 per diluted share in Q3 2023, with a net income margin of 18.1%[5] - Net income for the nine months ended September 30, 2024, was $287,368,000, up 40.4% from $204,512,000 in the same period of 2023[19] - Basic net income per share attributable to common shareholders for the three months ended September 30, 2024, was $3.11, compared to $2.30 for the same period in 2023, reflecting a 35.2% increase[19] - Full year 2024 GAAP net income is projected to be between $376.0 million and $388.0 million[9] Cash Flow and Liquidity - Cash and cash equivalents were $656.9 million as of September 30, 2024, with $149.1 million generated in cash flow from operating activities during Q3 2024[8] - Cash and cash equivalents rose significantly to $656,900,000 as of September 30, 2024, compared to $245,449,000 at the end of 2023, indicating a 167.5% increase[21] Backlog and Business Awards - Net new business awards in Q3 2024 were $533.7 million, a decrease of 12.7% from $611.5 million in Q3 2023, resulting in a net book-to-bill ratio of 1.00x[4] - Backlog as of September 30, 2024, increased by 8.8% to $2,927.4 million from $2,689.5 million in the prior year[4] Operating Expenses and EBITDA - EBITDA for Q3 2024 increased by 31.7% to $118.8 million, representing an EBITDA margin of 22.3%, compared to $90.2 million and 18.3% in Q3 2023[5] - EBITDA for the nine months ended September 30, 2024, was $346,672,000, compared to $266,663,000 for the same period in 2023, reflecting a 30.0% increase[26] Shareholder Equity and Repurchase Program - Total shareholders' equity rose to $881,439,000 as of September 30, 2024, compared to $558,950,000 at the end of 2023, indicating a 57.7% increase[22] - The company had $308.8 million remaining under its authorized share repurchase program as of September 30, 2024[8] Advanced Billings - Advanced billings increased to $670,939,000 as of September 30, 2024, from $559,860,000 at the end of 2023, showing a 19.8% growth[21]